![]() |
市場調查報告書
商品編碼
1504211
阿茲海默症治療藥的市場規模,佔有率,預測,趨勢分析:藥物,各用途-2031年前的全球預測Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor, NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management) - Global Forecast to 2031 |
阿茲海默症藥物市場預計到2031年將達到96.2億美元,2024年至2031年複合年增長率為9.8%
該報告在廣泛的二級和一級研究以及對市場情景的深入分析後,對主要市場驅動因素、限制因素、課題和機會進行了分析。該市場的成長是由阿茲海默症全球負擔日益加重、風險因素患病率上升、研究經費增加、創新技術引進、批准數量增加、臨床試驗和管道產品數量增加等推動的。各種因素。然而,藥物可能產生的副作用和替代療法的使用正在限制市場成長。
此外,新興市場研究活動的增加、意識計劃的提高、公共和私人組織的舉措、聯合藥物療法的使用、生物標記物和成像技術用於診斷和管理等的使用預計將為參與者提供成長機會經營這個市場。然而,阿茲海默症藥物研發成本高、臨床試驗失敗率高、審批流程長且複雜,為市場成長帶來重大課題。
(註:提供前 5 名公司 SWOT 分析)
Alzheimer's Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor [Donepezil, Galantamine, Rivastigmine], NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management)-Global Forecast to 2031
The Alzheimer's Drugs Market is Projected to Reach $9.62 Billion by 2031 at a CAGR of 9.8% From 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. However, possible side effects of drugs and the use of substitute treatments are restraining the market growth.
Furthermore, growing research activities in developing countries, an increase in awareness programs, initiatives by public and private organizations, the use of combination drug therapy, and the use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities to the players operating in this market. However, the high cost of research and development, the high failure rate in clinical trials, and the lengthy and complex regulatory approval process for Alzheimer's drugs are major challenges to the market's growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the Alzheimer's drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), Supernus Pharmaceuticals Inc. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan).
Among all the drug types studied in this report, in 2024, the cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer's drugs market. The cholinesterase inhibitors segment is further divided into donepezil, galantamine, and rivastigmine. The large share of the segment is attributed to the rising prevalence of Alzheimer's disease, the increasing aging population, rising approval for cholinesterase inhibitors, and the increasing effectiveness of drugs. Additionally, donepezil is used to treat all the stages of Alzheimer's disease, that is, early, middle, and late, further increasing the demand for these drugs, thus contributing to the largest share of the segment.
Among all the applications studied in this report, in 2024, the symptom management segment is expected to account for the largest share of the Alzheimer's drugs market. The symptom management segment is further divided into dementia, insomnia, and other symptoms. The large share of the segment is attributed to the availability of a greater number of symptom-management drugs compared to disease progression and increasing focus on symptom management. The focus on symptom management is increasing to slower the disease progression to reduce the cost and healthcare resources associated with it. Additionally, symptom management improves the patient's quality of life, reduces dependency on caregivers, and improves patient safety by addressing the symptoms of dementia, impaired judgment, and confusion symptoms.
An in-depth analysis of the geographical scenario of the global Alzheimer's drugs market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the Alzheimer's drugs market. The largest share of the region is attributed to the increasing prevalence of Alzheimer's disease, rising number of clinical trials for Alzheimer's drugs, increasing funding for the development of Alzheimer's drugs, and increasing awareness programs. Also, supportive government initiatives to reduce the prevalence of Alzheimer's disease are further contributing to the largest share of the segment. For instance, the U.S. Department of Health and Human Services signed a law, namely, the National Alzheimer's Project Act (NAPA). The objective of NAPA is to prevent and effectively treat Alzheimer's disease by 2025.
Alzheimer's Drug Market Assessment-by Drug Type
Alzheimer's Drug Market Assessment-by Application
Note: Other symptoms include loss of spontaneity, depression, hallucination, or paranoia.
Alzheimer's Drug Market Assessment-by Geography
(Note: SWOT analyses of the top 5 companies will be provided.)